However, the role of CD133 in general and specifically in melanoma remains highly controversial; there is no conclusive evidence regarding whether CD133-negative (CD133neg) subpopulations can initiate tumors (Zimmerer et al., 2016, González-Herrero et al., 2013; Yde et al., 2018; Fomeshi et al., 2016; Rappa et al. 2008; Zimmerer et al., 2013; Roudi et al., 2015; Monzani et al., 2007). Here, PROM1 is linked to melanoma.